Last reviewed 2026-06-02 · How we verify

Eticlordifene (ETOFAMIDE)

Phase 2 active Small molecule

Eticlordifene (generic name: ETOFAMIDE) is a etofamide drug. It is currently in Phase 2 development.

Etofamide is thought to work by inhibiting a specific enzyme or protein, although the exact details of its mechanism are not yet fully understood.

Eticlordifene, also known as Etofamide, is a small molecule drug in the etofamide class. Its target and exact mechanism of action are unknown, but it is being developed for potential therapeutic applications. The commercial status of Etofamide is unclear, and it has not been approved by the FDA for any indications. Further research is needed to determine its efficacy and safety profile. As a result, key safety considerations and approved indications are currently unavailable.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ETOFAMIDE
Drug class	etofamide
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like a factory, and Etofamide is a tool that helps regulate the factory's production line. By inhibiting a specific enzyme or protein, Etofamide may help slow down or stop the production of certain molecules that contribute to disease. This can potentially lead to therapeutic benefits, but more research is needed to confirm its effects.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Eticlordifene CI brief — competitive landscape report
Eticlordifene updates RSS · CI watch RSS

Frequently asked questions about Eticlordifene

What is Eticlordifene?

Eticlordifene (ETOFAMIDE) is a etofamide drug.

How does Eticlordifene work?

Etofamide is thought to work by inhibiting a specific enzyme or protein, although the exact details of its mechanism are not yet fully understood.

What is the generic name of Eticlordifene?

ETOFAMIDE is the generic (nonproprietary) name of Eticlordifene.

What drug class is Eticlordifene in?

Eticlordifene belongs to the etofamide class. See all etofamide drugs at /class/etofamide.

What development phase is Eticlordifene in?

Eticlordifene is in Phase 2.

Drug class: All etofamide drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing